NasdaqCM:IMTXBiotechs
How Investors May Respond To Immatics (IMTX) Advancing Its PRAME Franchise With New ASCO 2026 Data
At the 2026 ASCO meeting, Immatics reported extended Phase 1 and 1b data showing deep, durable responses and manageable safety for its PRAME-targeted cell therapies and IMA401 bispecific across multiple hard-to-treat solid tumors, reinforcing progress of its lead programs in advanced melanoma, gynecologic cancers, synovial sarcoma, and head and neck cancer.
A distinctive takeaway is how Immatics is building an integrated PRAME franchise, spanning TCR T-cell therapies and bispecifics, aimed...